Eli Lilly was among the investors in neurodegenerative disease drug developer Vanqua Bio’s $85m series B round.

Vanqua Bio, a US-based developer of treatments for neurodegenerative diseases, emerged from stealth yesterday with $85m in series B funding from investors including pharmaceutical firm Eli Lilly.

Omega Funds led the round, which also featured OrbiMed, Surveyor Capital, Avoro Ventures, Casdin Capital, Pontifax, Osage University Partners and Logos Capital.

Founded in 2019 as Surmount Bio, Vanqua Bio is working on therapies that can slow or halt the progression of neurodegenerative conditions including Parkinson’s (PD), Alzheimer’s (AD), Gaucher disease and amyotrophic…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn